REVIEW article
Front. Cell Dev. Biol.
Sec. Signaling
Neoantigens in Cancer Immunoediting: From Mechanisms to Personalized Vaccines in Breast Cancer
Provisionally accepted
- 1Sichuan Cancer Hospital and Institute, Chengdu, China
- 2Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Tumor neoantigens, a class of entirely novel antigens generated by somatic mutations, can be specifically recognized by T cells and serve as a central bridge connecting tumor genomic variation with anti-tumor immune responses. This review systematically elaborates on the dual role of neoantigens in the dynamic process of immunoediting: they act as targets for immune attack that are "sculpted" and as drivers of tumor evolution that are "selected." It further explores their immense potential as targets for personalized immunotherapy. By delving into the mechanisms of neoantigen generation, identification strategies, and their pivotal role within the cancer-immunity cycle, the review focuses on the latest advances in neoantigen-based DNA, RNA, and synthetic peptide vaccines. Notably, drawing on a first-in-human clinical trial of a neoantigen DNA vaccine in triple-negative breast cancer (TNBC), it validates the safety, clinical feasibility, and potent immunogenicity of this therapeutic strategy. Finally, the article discusses how to address core challenges such as tumor heterogeneity and immune escape by integrating cutting-edge strategies including artificial intelligence prediction, rational multi-epitope design, and combination therapies. This provides a solid theoretical foundation and promising clinical translation prospects for personalized immunotherapy in breast cancer and other solid tumors.
Keywords: DNA vaccine, Immunoediting, neoantigen, personalized vaccine, Triple-negative breast cancer, tumor heterogeneity
Received: 27 Oct 2025; Accepted: 09 Dec 2025.
Copyright: © 2025 Zeng, Wang, Zeng and SUN. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: LEI SUN
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.